New FDA Framework Limits Fall Vaccinations to High-Risk Groups Only
In a major policy shift, the United States will no longer routinely approve annual Covid-19 shots for healthy adults and children, according to new guidelines issued by the Food and Drug Administration (FDA) on Tuesday.
Under the updated framework, only adults aged 65 and above and individuals—both adults and children—with underlying health conditions that place them at higher risk will be eligible for annual Covid-19 vaccinations. The move significantly changes how the US government approaches Covid vaccination, moving away from the previous “one-size-fits-all” strategy.
Published in the New England Journal of Medicine, the FDA framework calls for extensive studies before authorizing Covid-19 boosters for healthy individuals. Officials aim to align the US strategy more closely with other countries and ensure vaccines target the people who need them most.
“We simply don’t know whether a healthy 52-year-old woman with a normal BMI who has had Covid-19 three times and has received six previous doses of a Covid-19 vaccine will benefit from the seventh dose,” wrote FDA Commissioner Dr. Marty Makary and vaccine chief Dr. Vinay Prasad in the journal article.
The new policy comes amid a broader reevaluation of the nation’s Covid-19 vaccination strategy under Health Secretary Robert F. Kennedy, who has filled top health positions with vocal critics of previous Covid vaccine mandates.
Health experts warn the decision could lead to reduced accessibility and insurance coverage for those who still want fall Covid shots but don’t meet the new high-risk criteria.
“Is the pharmacist going to determine if you’re in a high-risk group?” asked Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia. “This will only make vaccines less available.”
While the Centers for Disease Control and Prevention (CDC) is expected to debate the new vaccine recommendations next month, some critics argue that the FDA’s move preempts that advisory panel’s role.
Despite the shift, data continues to support the efficacy of booster doses in providing short-term protection—particularly against mild to moderate illness—even among healthy individuals.
As of now, the future of widespread Covid-19 vaccination remains uncertain, with 100 to 200 million Americans potentially still qualifying under the new guidelines. The coming months will reveal how this decision impacts vaccine uptake and public health outcomes in the US.
